Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;41(4):472-478.
doi: 10.1177/0333102421997093. Epub 2021 Feb 25.

Diagnosis and treatment of idiopathic intracranial hypertension

Naz Raoof  1   2 , Jan Hoffmann  3   4
Affiliations
Review

Diagnosis and treatment of idiopathic intracranial hypertension

Naz Raoof et al. Cephalalgia. 2021 Apr.

Abstract

Objective: To review and discuss the clinical presentation and treatment of idiopathic intracranial hypertension.

Discussion: Visual alterations and headache are the two main symptoms of idiopathic intracranial hypertension, although additional features including cranial nerve palsies, cognitive deficits, olfactory deficits and tinnitus are not uncommon. The headache associated with idiopathic intracranial hypertension frequently has a migrainous phenotype. The underlying cause of the disorder has not yet been elucidated. Several hypotheses have been postulated but none of them can explain the full clinical picture. Therapeutic options remain limited, focusing mainly on reduction in body weight and the reduction of CSF production with carbonic anhydrase inhibitors.

Conclusion: The accurate diagnosis of idiopathic intracranial hypertension is essential as visual deterioration due to papilledema may be irreversible. Given its phenotypic similarity and frequent overlap with chronic migraine it is essential to consider idiopathic intracranial hypertension in the diagnostic workup of chronic headache; in particular, when considering its increasing prevalence. Understanding in detail the pathophysiological mechanisms behind the associated headache would also allow study of current and future therapeutic options in a structured way.

Keywords: Idiopathic intracranial hypertension (IIH); headache; pain; papilledema.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: NR does not report a conflict of interest. JH has received honoraria for serving on advisory boards, consulting activities and/or for presentations from Allergan, Autonomic Technologies Inc, Cannovex BV, Chordate Medical AB, Eli Lilly, Hormosan Pharma, Lundbeck, Novartis, Sanofi and Teva. He has received personal fees for medico-legal work as well as from Sage Publishing, Springer Healthcare and Quintessence Publishing. He has received research support from Bristol Myers Squibb. None of these activities and honoraria are related to the submitted work.

References

    1. Markey KA, Mollan SP, Jensen RH, et al.. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol 2016; 15: 78–91. - PubMed
    1. Wall M, McDermott MP, Kieburtz KD, et al.. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: The idiopathic intracranial hypertension treatment trial. JAMA 2014; 311: 1641–1651. - PMC - PubMed
    1. Headache Classification Committee of the International Headache Society . The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1–211. - PubMed
    1. Mollan SP, Hoffmann J, Sinclair AJ. Advances in the understanding of headache in idiopathic intracranial hypertension. Curr Opin Neurol 2019; 32: 92–98. - PMC - PubMed
    1. Sadun AA, Currie JN, Lessell S. Transient visual obscurations with elevated optic discs. Ann Neurol 1984; 16: 489–494. - PubMed

LinkOut - more resources